What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?

Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the management of multiple malignancies including lung cancer. However, the optimal use of these agents in terms of duration, dose and administration frequency remains unknown. Focusing on anti-PD1 agents nivolumab and pembro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuah, Chii Yang, Monfries, Robert, Quartagno, Matteo, Seckl, Michael J., Ghorani, Ehsan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638879/
https://www.ncbi.nlm.nih.gov/pubmed/37954230
http://dx.doi.org/10.1177/17588359231210271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638879/
https://www.ncbi.nlm.nih.gov/pubmed/37954230
http://dx.doi.org/10.1177/17588359231210271

Ejemplares similares